课题基金 / 基金详情

Phagocyte-derived S100A12 complexes and T cell expression of IL-17/IFNγ as factors linking innate and adaptive immune dysregulation in systemic Juvenile Idiopathic Arthritis (sJIA)

Phagocyte-derived S100A12 complexes and T cell expression of IL-17/IFNγ as factors linking innate and adaptive immune dysregulation in systemic Juvenile Idiopathic Arthritis (sJIA)
吞噬细胞衍生的 S100A12 复合物和 IL-17/IFNγ 的 T 细胞表达作为系统性幼年特发性关节炎 (sJIA) 中先天性和适应性免疫失调的因素
批准号:
407661645
负责人:
Professor Dr. Dirk Föll
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2018
资助国家:
德国
项目状态:
已结题
起止时间:
2017-12-31 至 2022-12-31

项目摘要

项目成果

Professor Dr. Dirk Föll的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Systemic Juvenile Idiopathic Arthritis (sJIA) is the most severe form of rheumatic joint disease in childhood. In its systemic phase, it is an autoinflammatory disease with significant morbidity. We have previously shown that phagocyte-derived calcium-binding S100 proteins contribute to autoinflammation in this initiation phase. S100A12 spontaneously released from autoinflammatory patient neutrophils is a pro-inflammatory "alarmin" that activates monocytes via Toll-like receptor 4 (TLR4) signalling and appears at high concentrations in active sJIA serum. Importantly, we just demonstrated that serum S100A12, in concert with particularly IL-1b and IL-18, can promote overexpression of ydT cellular IL-17 in sJIA. IL-17 overexpression by ydT cells appears particularly sensitive to therapeutic IL-1b blockade. On the contrary, sJIA CD4+ T cells did not reveal increased IL-17 expression but mounted a surprisingly limited IFNy response. Our patient data are in striking line with a recently proposed sJIA mouse model, which presented its most pronounced clinical phenotype on IFNy-/- background and depends on IL-17 expressing ydT cells in disease pathology. IFNy is considered as potential master-switch in sJIA: Murine model as well as our patient data indicate low levels to contribute to the progression of autoimmune arthritis, while IFNy-overexpression may drive macrophage activation syndrome (MAS) as one of the most severe systemic sJIA complications. Our present proposal aims to understand the skewing of T cellular cytokine expression in sJIA, with emphasis on dysbalanced IFNy. CD4+ T cells will be studied for lineage differentiation and expansion of cytokine expressing cells, particularly in presence of serum factors such as S100A12, IL-1, IL-18 and IL-6 as over-expressed in sJIA, or IL-7 and IL-15 as differentially regulated by S100A12. Further, we will investigate the contribution of CD8+ T cells to cytokine signatures in sJIA and their role in modulating cytokine expression by CD4+ T cells. Yet unpublished data from our sJIA-patient studies suggest a massive upregulation of IFNy by particularly CD8+ T cells and these cells to negatively regulate CD4+ T cellular cytokine expression. Finally we aim to sudy the contribution of S100A12 to disease development in the sJIA mouse model, utilizing S100A12tg animals on wildtype as well as IFNylow or IFNy-/- background. Our overall goal is to understand whether the sterile inflammatory environment in sJIA, characterized by a strong overexpression of the endogenous TLR4 ligand S100A12, can result in a unique cytokine environment polarizing IL-17 and IFNy production to distinct cell populations, which are crucial for sJIA pathogenesis. Understanding the cross-talk between innate and adaptive immunity may help to better understand the natural course of this debilitating disease and foster the generation of more targeted approaches to monitor and treat sJIA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A comprehensive clinical and experimental approach to personalized molecular medicine in patients with defined and undefined autoinflammatory disorders
Molecular mechanisms underlying the S100A12-mediated activation of phagocytes: Interaction with cellular receptors and function as "damage associated molecular pattern" protein
Die Bedeutung des granulozytären Proteins S100A12 in Entzündungen: Sekretion, Rezeptorbindung und pro-inflammatorische Effekte
国内基金
海外基金
tRNA-derived small RNA上调YBX1/CCL5通路参与硼替佐米诱导慢性疼痛的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    张祥忠
  • 依托单位:
一类DMOA-Derived Meroterpenoid的全合成研究
  • 批准号:
    22071192
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2020
  • 负责人:
    胡向东
  • 依托单位:
TET1/exosome-derived miR-22-3p/BTG1信号轴在膀胱癌化疗耐药中的作用与分子机制
  • 批准号:
    82072807
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    肖峻
  • 依托单位:
基于寨卡病毒NS1和NS5的海洋微生物中抗病毒化合物的发现
  • 批准号:
    81973204
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2019
  • 负责人:
    宋福行
  • 依托单位: